Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Mar 7, 2024
Discovery & Translation
Science spotlight: Roche’s anti-TIGIT mAb benefits from Fc-driven effects and more
BioCentury’s roundup of translational innovations
BioCentury | Oct 25, 2022
Regulation
Accumulus Synergy: modernizing interactions with and among regulators
Cloud-based platform aims to enable real-time information sharing to accelerate drug development, promote innovation
BioCentury | Aug 26, 2021
Product Development
COVID Quick Takes: Moderna completes SpikeVax submission for full approval
Plus: Brii’s Phase III readout, approval Down Under for Vir, and updates from Pfizer-BioNTech, J&J
BioCentury | Sep 17, 2019
Regulation
FDA’s international drug review pilot could simplify cancer trials, get drugs to patients faster
FDA’s new joint international oncology drug review process could help companies and patients
BioCentury | Apr 17, 2018
Politics & Policy
Australia to evaluate Lilly's Lartruvo under new provisional pathway
Items per page:
1 - 10 of 97